Open Forum Infectious Diseases journal. Investigational monoclonal antibody therapies, administered intravenously, are specifically designed to block infection by SARS-CoV-2, the virus that causes covid-19.
Similar to antibodies which are proteins that the body naturally produces to defend itself against disease, monoclonal antibodies are artificially created in the lab, tailor-made to fight the disease they treat.
The therapy is being frequently used in India and several parts of the world for the treatment of covid-19. The FDA has granted emergency use authorization (EUA) of MABs in outpatients with mild-to-moderate covid-19 at increased risk of developing severe disease.